Last reviewed · How we verify
vancomycin, teicoplanin or daptomycin — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
vancomycin, teicoplanin or daptomycin (vancomycin, teicoplanin or daptomycin) — Aziende Chimiche Riunite Angelini Francesco S.p.A.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| vancomycin, teicoplanin or daptomycin TARGET | vancomycin, teicoplanin or daptomycin | Aziende Chimiche Riunite Angelini Francesco S.p.A | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- vancomycin, teicoplanin or daptomycin CI watch — RSS
- vancomycin, teicoplanin or daptomycin CI watch — Atom
- vancomycin, teicoplanin or daptomycin CI watch — JSON
- vancomycin, teicoplanin or daptomycin alone — RSS
Cite this brief
Drug Landscape (2026). vancomycin, teicoplanin or daptomycin — Competitive Intelligence Brief. https://druglandscape.com/ci/vancomycin-teicoplanin-or-daptomycin. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing